{
  "scenario_id": "pharmaceutical_companion_diagnostics_investment_2025",
  "context": "Large pharmaceutical company evaluating investment in companion diagnostics for personalized medicine pipeline",
  "stakeholders": {
    "requester": "VP Personalized Medicine",
    "approvers": [
      "Chief Scientific Officer",
      "CFO",
      "Chief Medical Officer"
    ],
    "influencers": [
      "Head of Diagnostics",
      "Regulatory Affairs Director",
      "VP Clinical Development"
    ]
  },
  "request": {
    "amount": "$15,000,000",
    "purpose": "Develop companion diagnostics platform for oncology and immunology therapies",
    "urgency": "medium",
    "justification": "Companion diagnostics required for 40% of pipeline therapies, enabling personalized treatment approaches"
  },
  "decision_process": [
    {
      "stage": "feasibility_assessment",
      "duration": "3 weeks",
      "activities": [
        "Technology platform evaluation",
        "Regulatory pathway analysis",
        "Market opportunity sizing"
      ],
      "outcome": "Strong strategic fit identified"
    },
    {
      "stage": "financial_modeling",
      "duration": "2 weeks",
      "activities": [
        "ROI analysis",
        "Partnership options assessment",
        "Risk-adjusted projections"
      ],
      "outcome": "Approved with phased investment approach"
    }
  ],
  "business_impact": {
    "expected_outcome": "Accelerated development of 5 companion diagnostics, improved therapy outcomes",
    "projected_value": "$200,000,000 in additional therapy revenue over 10 years",
    "risk_factors": [
      "Regulatory approval delays",
      "Technology development challenges",
      "Market adoption uncertainty"
    ]
  },
  "decision_criteria": [
    "Strategic alignment with personalized medicine",
    "Regulatory feasibility",
    "Financial return potential",
    "Technology readiness",
    "Market demand"
  ],
  "outcome": "Approved",
  "lessons_learned": "Early regulatory engagement critical for companion diagnostics, phased investment reduces execution risk"
}
